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in study design and the availability of evidence for value demonstration. System-
atic reviews and retrospective database studies investigating the efficacy and
safety of existing therapies or supportive care, which allow for qualitative compar-
isons against the new therapy, were generally expected by most of the respon-
dents. Cost-effectiveness analysis was required in some of the countries, with the
rest expecting only a budget-impact analysis based on local epidemiological data.
Findings were similar for therapies for diseases with low prevalence but without
orphan drug designation. CONCLUSIONS: Unmet needs in rare diseases are high,
and effective new therapies are welcomed and valued by payers in these key reim-
bursed markets in Asia. Decision makers are willing to show a degree of flexibility
in their evidence requirements for these kinds of products.
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OBJECTIVES: To examine the indicators of success in reimbursement application
in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and
describe the rationale behind it. Of interest is whether or not listing on the Phar-
maceutical Benefit Scheme (PBS) is recommended based on the clinical evidence,
the cost-effectiveness outcomes, political will, and whether there is clarity in the
recommendations made for the subsidisation of drugs on the PBS. This examina-
tion is conducted in order to shed light on the basis of decision making and the
impact of economic evaluations.METHODS: Themethod used in this analysis was
to differentiate the medicines into those that have never been subsidised, those
that are currently subsidised and those seeking listing of a new indication. Subse-
quently the rationales for a positive or negative recommendation for a PBS listing
are reviewed and assessed using Public Summary Documents (PSD’s). A the least
squares linear regression analysis was undertaken in order to determine which
variable impacted significantly on the PBAC’s recommendation. RESULTS: In 2007,
following 1 years worth of PSD’s, the recommendations made by the PBAC were
analysed and presented at the European iHEA. Five years later this paper presents
a follow-up to that initial research and explores the recommendationsmade by the
PBAC and the incremental cost-effectiveness ratios (ICER)which have factored into
the reimbursement recommendations. Changes in the thresholds are explored and
discussed. CONCLUSIONS: The PSD documents are now providing researchers
with an opportunity to appreciate the decision making process and what influ-
ences bare upon a key decision maker, the PBAC. It sets an example of explicit
decision making. The question that remains, however, is how transparent are the
rules and whether the outcomes confirm the perceived league table.
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OBJECTIVES: In general, demonstrating cost-effectiveness for orphan drugs in-
cluding orphan oncology agents is challenging. Reasons include high incremental
cost per QALY and insufficient clinical evidence. Even in an established Health
Technology Assessment (HTA) system such as the UK, orphan oncology agents are
often rejected as they are not cost-effective. In Asia-Pacific, South Korea and Aus-
tralia employ a similar HTA system.HTA recommendations between the countries,
however, are not always comparable. This research aims to understand the drivers
for positive recommendations and implications for improved patient access to
oncology treatments. METHODS: Review HTA recommendations in UK, Australia
and South Korea for sunitinib, dasatinib, lenalidomide, imatinib and rituximab.
Compare and contrast prices, level of clinical evidence and reimbursed patient
populations in the context of the specific assessment criteria in each country.
Identify drivers for positive recommendations. RESULTS: Of the selected drugs,
more have received positive recommendations in South Korea and Australia than
UK. A drug that receives a positive recommendation is usually priced lower in
South Korea thanAustralia or the UK. BetweenAustralia andUK, Australia tends to
reimburse at a lower price. The level of clinical evidence has less impact on eval-
uations in South Korea. In the UK, if NICE recommends an orphan oncology drug,
usually a patient access scheme is included. CONCLUSIONS: While pricing is not
dictated by NICE in the UK, access remains highly regulated. Manufacturers often
need to set up patient access schemes in order to prove their orphan oncology
drugs cost-effective and optimize patient access. On the other hand, in South Ko-
rea, the HTA process is less defined and more driven by minimizing costs. While
cost-effectiveness is the main driver for a positive recommendation, formal price
negotiation processes in South Korea and Australia lead to access more consis-
tently.
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OBJECTIVES: In Japan, introduction of economic evaluation of health policy issues
such as pricing and reimbursement of drugs and medical devices is gaining atten-
tion; several research guidelines have been proposed for the same. We compared
the key features of these guidelines and obtained suggestions for future research.
METHODS: We reviewed literature using the Ichushi database (Japanese medical
literature database) and the database on government-funded research reports, and
also contacted investigators and experts for related information. RESULTS: Four
guidelines were identified: Shiragami (2004) and Kamae (2007) groups, funded by
theMinistry of Health andWelfare, Japan, proposed two guidelines on pharmaceu-
tical pricing. The task force of the Ministry of Economy, Trade and Industry, Japan
(2007) proposed one guideline on medical device policy. The Hirota group (2011),
funded by the Ministry of Health and Welfare, Japan, proposed one guideline on
vaccination strategy. Although the headings and structures of all guidelines were
almost similar, significant differences were identified among them. For example,
two guidelines recommended societal perspective, while the other two recom-
mended consumer’s perspective. In terms of outcomemeasures, QALYs were pre-
ferred in three guidelines, whereas one recommended “the proportions of patients
who achieved target clinical results within 2 years.” Trial use was not conducted to
verify the feasibility of guidelines, except for the Hirota guideline for vaccination
policy. In addition, some recommendations had a serious problem in terms of
scientific rationality. CONCLUSIONS: There are significant variations in the key
features among all four abovementioned guidelines, and even between the two
sets of guidelines for pharmaceutical pricing decisions. To use an economic eval-
uation to aid rational resource allocation, official guidelines should be established
with scientific rigor and integrity, and future discussions about feasibility are
needed among various representatives from government, academia and industry.
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OBJECTIVES: To evaluate a Multidisciplinary Perspectives Intervention with Com-
munity Involvement (MPI&CI) which was implemented to reduce antibiotics sales
in village groceries which were illegal based on Thai Drug Act (1967). METHODS:
MPI&CI was developed based on information obtained from focus groups that in-
cluded multidisciplinary stakeholders. The intervention consisted of 1) communi-
cation about antibiotic knowledge; 2) investigation of availability of antibiotics in
groceries; and 3) informing grocery owners when antibiotics were found for sale in
their groceries. Community leaders in the intervention group were trained in a
one-dayworkshop to implementMPI&CI in their villages. A quasi-experimentwith
pretest posttest measurement was conducted to assess the effect of MPI&CI. Data
were collected from 20 villages in one district in Mahasarakham Province (inter-
vention group), and in another 20 villages in a different district in the same prov-
ince (comparison group). A generalized linear mixed model poisson regression
with repeated measures was used to evaluate the effectiveness of MPI&CI.
RESULTS: The results indicated that the intervention was effective at reducing the
number of antibiotics available for sale in groceries. Groceries in the intervention
group had 87% fewer antibiotics available at post-intervention compared with pre-
intervention (relative rate 0.13, 95% CI 0.07, 0.23), while the control group had only
an 8% reduction in antibiotic availability (relative rate 0.92, 95% CI 0.88, 0.97) be-
tween the two time periods. CONCLUSIONS: This study suggested that community
involvement during development and implementation of the intervention is an
effective approach for reducing antibiotics sales in village groceries in Thailand.
Further study should be developed to assess the sustainability and long-term ef-
fectiveness of MPI&CI.
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OBJECTIVES: Interprofessional collaboration and team-based care have been re-
garded as important approaches to improve health care. Factors enhancing and
prohibiting interprofessional collaboration in practice settings, however, are not
fully understood. This study provides an updated literature review on factors in-
fluencing interprofessional collaboration from 2004-2011. METHODS: Databases
including ABI/INFORM Global, CINAHL Plus, MEDLINE, PsycINFO, Sociological Ab-
stracts, and ProQuest Dissertations & Theses were searched using keywords such
as collaboration, team, interprofessional, interdisciplinary, determinant, and fac-
tor; and subject headings such as interprofessional relations (MeSH) and multidis-
ciplinary care team (CINAHL). Only empirical studies conducted in patient care
settings examining interprofessional collaboration were retained. Due to the large
number of hits, article titles were screened prior to abstract screening and retrieval
of full articles. Salient systematic, organizational, and interactional factors identi-
fied from the articles were summarized respectively. RESULTS: Over 7000 article
titles were screened, 680 abstracts were retrieved, and 110 articles were retained. A
wide range of qualitative (N66), quantitative (N34), and mixed methods (N10)
were used in these studies. The main systematic factors included regulatory and
economic incentives, as well as professional culture differences and dominance of
medical power. Organizational factors included leadership, physical space, staff-
ing, and team training. Interactional factors, which have been studied the most
extensively, included communication, team climate, shared purpose, awareness
and respect. Additional factors included complexity of patient cases and team
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